Two of five trials (26, 28) in patients with NSCLC enrolled any patients with EGFR or ALK mutations: in one trial, 113 (9%) of 1225 patients had EGFR mutation and 5 (<1%) had ALK mutation (26); in the other, 82 (14%) of 582 patients had EGFR mutation and 21 (4%) had ALK mutation (28). This evidence concerns the gene ALK and non-small cell lung carcinoma.